The findings were published on Friday, days after an American biotechnology company announced that it had also developed a vaccine that has been found to be safe and able to stimulate an immune response in the human body against the virus.

The study on 108 adults found that one dose of the vaccine, known as recombinant adenovirus type-5 vectored Covid-19 vaccine (AD5), tested at three different levels on healthy adults aged between 18 and 60 years, appeared to induce a good immune response in some subjects.

The researchers tested the blood of volunteers (enrolled from one site in Wuhan) at regular intervals following vaccination to see whether the vaccine stimulated both arms of the immune system: the body’s ‘humoral response — the part of the immune system that produces neutralising antibodies, which can fight infection and could offer a level of immunity — and the body’s cell-mediated arm, which depends on a group of T cells, rather than antibodies, to fight the virus.

The trial demonstrates that a single dose of the new adenovirus type 5 vectored Covid-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” said Prof Wei Chen from the Beijing Institute of Biotechnology, who is responsible for the study.

The challenges in the development of a Covid-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from Covid-19.

BlackFacts Details

Covid-19: Western Cape plans to expand Jabs before Jol campaign | News24

New York City Facts

Education Facts

Women Facts